Coherus Oncology, Inc.
CHRSNASDAQHealthcare● Active
$1.45
$-0.00(-0.34%)
Market Cap$176894577
P/E Ratio—
52W High$2.616
52W Low$0.71
Coherus Oncology, Inc. (CHRS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CHRS · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 11, 2026EPS Actual
-$0.25
Est. -$0.26 · +5.1%
Revenue
$0.01B
Est. $0.01B · -13.4%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 11, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 2-Quarter EPS Beat Streak
CHRS reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.12 | — | — | — | $0.02B | — |
| ▲ Q2 FY2026 | May 11, 2026 | -$0.26 | -$0.25 | +5.1% | $0.01B | $0.01B | -13.4% |
| ▲ Q1 FY2026 | Mar 9, 2026 | -$0.36 | -$0.34 | +4.3% | $0.01B | $0.01B | -8.4% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$0.32 | -$0.33 | -3.1% | $0.01B | $0.01B | -17.9% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$0.31 | -$0.34 | -9.7% | $0.01B | $0.01B | -14.4% |
| ▼ Q2 FY2025 | May 12, 2025 | -$0.31 | -$0.35 | -12.9% | $0.01B | $0.06B | -87.5% |
| ▼ Q1 FY2025 | Mar 10, 2025 | -$0.10 | -$0.28 | -180.0% | $0.05B | $0.06B | -9.8% |
| ▲ Q4 FY2024 | Nov 6, 2024 | -$0.10 | -$0.01 | +90.0% | $0.07B | $0.04B | +61.3% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.12
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 11, 2026Beat
EPS Actual
-$0.25
EPS Est.
-$0.26
EPS Surpr.
+5.1%
Revenue
$0.01B
Q1 FY2026
Mar 9, 2026Beat
EPS Actual
-$0.34
EPS Est.
-$0.36
EPS Surpr.
+4.3%
Revenue
$0.01B
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$0.33
EPS Est.
-$0.32
EPS Surpr.
-3.1%
Revenue
$0.01B
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$0.34
EPS Est.
-$0.31
EPS Surpr.
-9.7%
Revenue
$0.01B
Q2 FY2025
May 12, 2025Miss
EPS Actual
-$0.35
EPS Est.
-$0.31
EPS Surpr.
-12.9%
Revenue
$0.01B
Q1 FY2025
Mar 10, 2025Miss
EPS Actual
-$0.28
EPS Est.
-$0.10
EPS Surpr.
-180.0%
Revenue
$0.05B
Q4 FY2024
Nov 6, 2024Beat
EPS Actual
-$0.01
EPS Est.
-$0.10
EPS Surpr.
+90.0%
Revenue
$0.07B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2027 | $-0.35 | $-0.19 | $-0.15 | 1 |
| Q3 FY2027 | $-0.35 | $-0.19 | $-0.15 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.1B | 2 |
| Q3 FY2028 | $0.0B | $0.0B | $0.1B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.1B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.1B | 2 |
| Q4 FY2027 | $0.0B | $0.0B | $0.1B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 11, 2026 | +5.1% | $1.75 | $1.95 | +11.43% |
| ▲ Q1 FY2026 | Mar 9, 2026 | +4.3% | $1.82 | $1.93 | +6.04% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -3.1% | $1.57 | $1.49 | -5.10% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -9.7% | $0.92 | $0.88 | -3.47% |
| ▼ Q2 FY2025 | May 12, 2025 | -12.9% | $0.97 | $1.02 | +5.30% |
| ▼ Q1 FY2025 | Mar 10, 2025 | -180.0% | $1.04 | $1.04 | +0.00% |
| ▲ Q4 FY2024 | Nov 6, 2024 | +90.0% | $0.73 | $0.72 | -0.98% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +33.3% | $1.24 | $1.29 | +4.03% |
Q2 FY2026+11.43%
Report Date
May 11, 2026
EPS Beat/Miss
+5.1%
Price Before
$1.75
Price After
$1.95
Q1 FY2026+6.04%
Report Date
Mar 9, 2026
EPS Beat/Miss
+4.3%
Price Before
$1.82
Price After
$1.93
Q4 FY2025-5.10%
Report Date
Nov 6, 2025
EPS Beat/Miss
-3.1%
Price Before
$1.57
Price After
$1.49
Q3 FY2025-3.47%
Report Date
Aug 7, 2025
EPS Beat/Miss
-9.7%
Price Before
$0.92
Price After
$0.88
Q2 FY2025+5.30%
Report Date
May 12, 2025
EPS Beat/Miss
-12.9%
Price Before
$0.97
Price After
$1.02
Q1 FY2025+0.00%
Report Date
Mar 10, 2025
EPS Beat/Miss
-180.0%
Price Before
$1.04
Price After
$1.04
Q4 FY2024-0.98%
Report Date
Nov 6, 2024
EPS Beat/Miss
+90.0%
Price Before
$0.73
Price After
$0.72
Q3 FY2024+4.03%
Report Date
Aug 8, 2024
EPS Beat/Miss
+33.3%
Price Before
$1.24
Price After
$1.29
Avg Beat Reaction+5.13%
Avg Miss Reaction-0.82%
Beat Rate4 / 8 quarters
Largest Move+11.43% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CHRS ends December
Coherus Oncology, Inc. (CHRS) most recently reported earnings on May 11, 2026 for Q2 FY2026, posting EPS of $-0.25 — beating the analyst consensus of $-0.26 by +5.1%. CHRS has beaten EPS estimates for 2 consecutive quarters. The next CHRS earnings date is expected around September 1, 2026.
Each quarter, investors track CHRS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CHRS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CHRS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CHRS earnings · 5 questionsCoherus Oncology, Inc.'s next earnings report is expected around September 1, 2026. CHRS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CHRS historically reports after market close (AMC).
CHRS earnings datewhen is CHRS earningsCHRS next earnings datewhen does CHRS report earningsCHRS earnings calendar
▸ Source: FMP · Coherus Oncology, Inc. SEC filings · US GAAP · Coherus Oncology, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026